BIBLIOGRAPHY
[1] Strauss SJ, Frezza AM, Abecassis N et al; ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: clinicalguidelines@esmo.org. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021 Dec;32(12):1520-1536. Doi: 10.1016/j.annonc.2021.08.1995. Epub 2021 Sep 6. PMID: 34500044.
[2] Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumors: news and perspectives. Pathologica. 2021 Apr;113(2):70-84. Doi: 10.32074/1591-951X-213. Epub 2020 Nov 3. PMID: 33179614; PMCID: PMC8167394.
[3] Newman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer. 2013;60(7):1113-1117
[4] Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Inter- group Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-3114.
[5] Thiel U, Wawer A, von Luettichau I, Bender HU, Blaeschke F, Grunewald TG, Steinborn M, Röper B, Bonig H, Klingebiel T, Bader P, Koscielniak E, Paulussen M, Dirksen U, Juergens H, Kolb HJ, Burdach SE. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. Oncotarget. 2016 Oct 25;7(43):70959-70968. doi: 10.18632/oncotarget.10938. PMID: 27486822; PMCID: PMC5342601.
[6] Martin McCabe, Laura Kirton, Maria Khan, Nicola Fenwick, Sandra J. Strauss, Claudia Valverde, Cristina Mata, Nathalie Gaspar, Roberto Luksch, Alessandra Longhi, Uta Dirksen, Marianne Phillips, Akmal Safwat, Hans Gelderblom, Thomas Kuehne, Jukka Kanerva, Andrew J. Westwood, Stefano Ferrari, Jeremy Whelan, and Keith Wheatley. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). Journal of Clinical Oncology, Volume 40, Number 17_suppl.doi.org/10.1200/JCO.2022.40.17_suppl.LB
[7] National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In: U.S: Department of Health and Human Services, 2017
[8] Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009;31 Pt 2:2416-32. Doi: 10.1016/j.clinthera.2009.11.020. PMID: 20110050.
[9] Hitron A, Steinke D, Sutphin S, Lawson A, Talbert J, Adams V. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. Journal of Oncology Pharmacy Practice. 2011;17(4):312-319. Doi:10.1177/1078155210380293
[10] Peter Mauch; Louis Constine; Joel Greenberger; William Knospe; Jessie Sullivan; Jane L. Liesveld; H.Joachim Deeg (1995). Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy. , 31(5), 1319–1339. Doi:10.1016/0360-3016(94)00430-s
[11] Fornari, Chiara; Oplustil O’Connor, Lenka; Pin, Carmen; Smith, Aaron; Yates, James W.T.; Cheung, S.Y. Amy; Jodrell, Duncan I.; Mettetal, Jerome T.; Collins, Teresa A. (2019). Quantifying Drug‐Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model. CPT: Pharmacometrics & Systems Pharmacology, (), psp4.12459–. doi:10.1002/psp4.12459
[12] Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, Deeg HJ. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39. Doi: 10.1016/0360-3016(94)00430-S. PMID: 7713791.
[13] Shao L, Wang Y, Chang J, Luo Y, Meng A, Zhou D. Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury. Transl Cancer Res. 2013 Oct;2(5):397-411. Doi: 10.3978/j.issn.2218-676X.2013.07.03. PMID: 24605290; PMCID: PMC3941916.
[14] Rafieemehr H, Maleki Behzad M, Azandeh S, Farshchi N, Ghasemi Dehcheshmeh M, Saki N. Chemo/radiotherapy-Induced Bone Marrow Niche Alterations. Cancer Invest. 2021 Feb;39(2):180-194. Doi: 10.1080/07357907.2020.1855353. Epub 2020 Dec 10. PMID: 33225760.
[15] Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol. 2021 May;106(5):662-672. Doi: 10.1111/ejh.13595. Epub 2021 Feb 16. PMID: 33544940; PMCID: PMC8248430.
[16] Ten Berg MJ, et al. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital- based cohort study. Drug Saf. 2011;34(12):1151–60. https://doi.org/10.2165/11594310-000000000-00000
[17] Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose-response and schedule dependence. J Clin Oncol. 1997 Jun;15(6):2378-84. Doi: 10.1200/JCO.1997.15.6.2378. PMID: 9196153.
[18] Merjaneh N, Young J, Mangoli A, Olsen M, Setty B, Lane A, Nagarajan R, Pressey JG, Turpin B. Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care. Pediatr Blood Cancer. 2022 Jul;69(7):e29548. Doi: 10.1002/pbc.29548. Epub 2021 Dec 28. PMID: 34962714.
[19] Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001 Feb 15;19(4):1137-46. Doi: 10.1200/JCO.2001.19.4.1137. PMID: 11181679.
[20] DA Silva, Levy C, Allouache D, Hrab I, Morel A, Faveyrial A, Gunzer K, Johnson A, Segura C, Licaj I, Damaj G, Emile G. Efficacy and Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone Marrow Infiltration. Anticancer Res. 2020. May;40(5):2955-2960. doi: 10.21873/anticanres.14274. PMID: 32366448
[21] Pahouja G, Wesolowski R, Reinbolt R, Tozbikian G, Berger M, Mangini N, Lustberg MB. Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. Cancer Treat Commun. 2015;3:28-32. doi: 10.1016/j.ctrc.2014.11.002. PMID: 25914871; PMCID: PMC4408922.
[22] Chan B, Lee JS, Yuan Y. Case report: An exceptional responder of low-dose continuous 5-FU in a patient with de-novo stage IV triple-negative breast cancer with liver and bone marrow failure. Front Oncol. 2024 Jan 15;13:1305584. doi: 10.3389/fonc.2023.1305584. PMID: 38288100; PMCID: PMC10823013.
[23] Milrod CJ, Binney G, Khan MA. Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma. Lancet Oncol. 2023 Dec;24(12):e519. doi: 10.1016/S1470-2045(23)00520-X. PMID: 38040004.
[24] Khan SJ, Ishaq I, Saeed H, Fayyaz MB, Baqari SAS, Wali RM. Bone Marrow Involvement in Metastatic Pediatric Ewing Sarcoma. J Coll Physicians Surg Pak. 2017 Aug;27(8):502-504. PMID: 28903844.
[25] Krsková L, Mrhalová M, Hilská I, Sumerauer D, Drahokoupilová E, Múdry P, Kodet R. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma. Virchows Arch. 2010 May;456(5):463-72. doi: 10.1007/s00428-010-0913-9. Epub 2010 Apr 20. PMID: 20405298.
[26] Germans SK, Weinberg OK. Metastatic angiosarcoma in a bone marrow biopsy. Blood. 2022 Nov 3;140(18):2001. doi: 10.1182/blood.2022018036. PMID: 36326791.
[27] Rosenberg AE, Garber JE, Bennett W, Bhan AK, Antman KH, Mark EJ. Epithelioid sarcoma with diffuse bone marrow metastases and associated leukemoid reaction. A case report and brief literature review. Am J Clin Pathol. 1988 Dec;90(6):723-6. doi: 10.1093/ajcp/90.6.723. PMID: 3057863.
[28] Jiang L, Admirand JH, Moran C, Ford RJ, Bueso-Ramos CE. Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. Ann Diagn Pathol. 2006 Dec;10(6):357-62. doi: 10.1016/j.anndiagpath.2005.11.005. PMID: 17126255.
[29] Cheng JJ, Mott RT, Savage PD, Paluri RK. Metastatic Alveolar Rhabdomyosarcoma with Extensive Bone Marrow Replacement in an Older Adult. Case Rep Oncol. 2021 Oct 21;14(3):1505-1510. doi: 10.1159/000519595. PMID: 34899243; PMCID: PMC8613543.
[30] Aida Y, Ueki T, Kirihara T, Takeda W, Kurihara T, Sato K, Shimizu I, Hiroshima Y, Sumi M, Ueno M, Ichikawa N, Watanabe M, Kobayashi H. Bone marrow metastasis of rhabdomyosarcoma mimicking acute leukemia: a case report and review of the literature. Intern Med. 2015;54(6):643-50. doi: 10.2169/internalmedicine.54.2473. Epub 2015 Jan 15. PMID: 25786457.